A study found that treatment with digitalis glycosides was associated with a lower risk of the composite of cardiovascular death or first worsening heart failure (HF) event in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with reduced ejection fraction (HFrEF).
The reduction was mainly through a lower risk of worsening HF events. No statistically significant interaction was observed with important study characteristics, including the extent of HF background therapy or type of digitalis glycosides treatment.
These results suggest digitalis glycosides may be used as additional medical therapy to reduce worsening HF events in this patient population.